and morning me Eva quarter of the Welcome today of corporate to XXXX. are our call you Thank good team. Mersana With for everyone. update the second several members
gastric expressing our non-small Officer. joined HERX-expressing patients Jack, lung Financial XMT-XXXX, I'm breast HERX Officer; Lowinger, Spellman, targeting Dolaflexin of our Dave Tim and a cell ADC studied Eva tumors, by to addition In cancer, in cancer will Chief a begin discussion with cancer. Scientific and being I with Chief
partial announced July XX, that X a FDA you phase hold. the As on clinical placed we know, on
no study clinical the the otherwise although drug While continued hold. with is patients receive will be resolution in to in levels of have partial the pending have enrolled the or participate the and protocol, current new consistent been participants in trial dose effect, ongoing hold
We to mitigation and in a panel have experts explore investigators risk worked strategies. of event the and reveal closely with detail
extremely submitted hold a moment to our the enable Mersana our I'd have employees We team, us the like providing a date, hold the clinical able of partial to thorough the trial, are we FDA, our with communications and response analysis FDA. are and believe for an clinical and to and this remains and changes with proposed hold and have the to Based patients. to of partial lift proceeding to protocol hard submit the proposal event our resume is thank on trial. hold lifted resume clinical to able enrolling being worked are Mersana further we about response will the FDA the both when the the a partners, Resolving to when new is and the to if priority, aligned the to lifted. who top take provide we with update optimistic we
clinical adverse hold the recent data partial second quarter, Annual Meeting on seven most in event at XMT-XXXX, our information presented in level at of dose ASCO series is clinical we in Although XXXX XMT-XXXX the on the June. the
cancer, X XX indicated breast DLT meter cancer data or six three patient. evaluation have one Toxicity period XXXX, Dose the per gallbladder Our Limiting levels dose April This included patients as square. HERX-amplified XX, that completed XX from across XX.X of cancer, to gastric milligrams
(inaudible) well of patients common fatigue, for being date, treatment was that and of events related and were manageable. and the most patients tolerated, those The As nausea, AST those adverse vomiting, grade of anemia, transient treatment low most elevations with ALT.
XX committed XX that's or the at at confirmed and have partial XX.X time, and level only resolve or meter disease We milligrams three completed first the period. the program. level patients XX better remain have stable from seven, development six per disclosure, dose dose enrolled dosed ASCO meter three XXXX of greater response. evaluation the hold the doses at including partial square, had Of of date the per of one milligrams continue clinical As been but including square to that the seven, to the patients
XXXX targeting Now, which those lung as is non-small currently XMT-XXXX, a through cancer first-in-class Dolaflexin dosing progressed as dose the XMT-XXXX tumor know, is several escalation. on and you entered as expressed types. ovarian to and rare which rapidly non-squamous in well of more in similar is broadly clinic other ADC cell level NaPiXb, epithelial XMT-XXXX. at It December has cancer, dose
our totality the certain of as considering at experience dosing evaluation, based evaluating this and well on dose doses escalation phase. to as the we are gain program and data half position believe data that be amendments to the a regimens. protocol date the following are the will in on first We XXXX, alternative (inaudible) data present to completion of in additional patient of We
in XXXX patients bring more area high and leveraging to need. forward on of position to leadership Mersana, profile committed the ADCs potentially by in cancer patients. therapies encouraged to unmet again look are this we’re At our important of We helping
Beyond Chief would discuss make XMT-XXXX and us turn are outline progress exciting the innovate to address needs. patient Scientific would and and Tim, like we to that XXXX, the Officer additional over doing new on we discovery now to our pipeline disclosure continue our allow call work I to on plan. are our platforms continuing to to
